Identification of a strongly activating human anti-CD40 antibody that suppresses HIV type 1 infection

AIDS Research and Human Retroviruses

Volumn 24, Issue 3, 2008, Pages 367-373

  Ellmark, Peter ^a   Andersson, Henrik ^a   Abayneh, Sisay ^a   Fenyö, Eva Maria ^a   Borrebaeck, Carl A K ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL INTERACTION; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; B-LYMPHOCYTES; CD40 LIGAND; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; HIV CORE PROTEIN P24; HIV-1; HUMANS; MICE;

EID: 41449108853     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0215     Document Type: Article

References (31)

1. Kornbluth RS, Kee K, and Richman DD: CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines. Proc Natl Acad Sci USA 1998;95:5205-5210.
2. Kornbluth RS: The emerging role of CD40 ligand in HIV infection. J Leukoc Biol 2000;68:373-382.
3. Kornbluth RS: An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection. J Hematother Stem Cell Res 2002;11:787-801.
4. Zhang R, Fichtenbaum CJ, Hildeman DA, Lifson JD, and Chougnet C: CD40 ligand dysregulation in HIV infection: HIV glycoprotein 120 inhibits signaling cascades upstream of CD40 ligand transcription. J Immunol 2004;172:2678-2686.
5. Schonbeck U and Libby P: The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001;58:4-43.
6. van Kooten C and Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000;67:2-17.
7. t Hart BA, Blezer EL, Brok HP, et al.: Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE. J Neuroimmunol 2005;163:31-39.
8. Boon L, Brok HP, Bauer J, et al.: Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J Immunol 2001;167:2942-2949.
9. Costello RT, Gastaut JA, and Olive D: What is the real role of CD40 in cancer immunotherapy? Immunol Today 1999;20:488-493.
10. Malmborg Hager AC, Ellmark P, Borrebaeck CA, and Furebring C: Affinity and epitope profiling of mouse anti-CD40 monoclonal antibodies. Scand J Immunol 2003;57:517-524.
11. Challa A, Pound JD, Armitage RJ, and Gordon J: Epitope-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and IgE synthesis in human B cells. Allergy 1999;54:576-583.
12. Pound JD, Challa A, Holder MJ, et al.: Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells. Int Immunol 1999;11:11-20.
13. Zhou Q, Gault RA, Kozel TR, and Murphy WJ: Immunomodulation with CD40 stimulation and interleukin-2 protects mice from disseminated cryptococcosis. Infect Immun 2006;74:2161-2168.
14. Geldart T and Illidge T: Anti-CD 40 monoclonal antibody. Leuk Lymphoma 2005;46:1105-1113.
15. Funakoshi S, Taub DD, Asai O, et al.: Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis. Leuk Lymphoma 1997;24:187-199.
16. Law CL, Gordon KA, Collier J, et al.: Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005;65:8331-8338.
17. Tai YT, Li X, Tong X, et al.: Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005;65:5898-5906.
18. Zhang R, Lifson JD, and Chougnet C: Failure of HIV-exposed CD4+ T cells to activate dendritic cells is reversed by restoration of CD40/CD154 interactions. Blood 2006;107:1989-1995.
19. di Marzio P, Mariani R, Lui R, Thomas EK, and Landau NR: Soluble CD40 ligand induces beta-chemokine production by macrophages and resistance to HIV-1 entry. Cytokine 2000;12:1489-1495.
20. Ellmark P, Esteban O, Furebring C, Malmborg Hager AC, and Ohlin M: In vitro molecular evolution of antibody genes mimicking receptor revision. Mol Immunol 2002;39:349-356.
21. Ellmark P, Ottosson C, Borrebaeck CA, Malmborg Hager AC, and Furebring C: Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library. Immunology 2002;106:456-463.
22. Khazaeli MB, Conry RM, and LoBuglio AF: Human immune response to monoclonal antibodies. J Immunother 1994;15:42-52.
23. Kasran A, Boon L, Wortel CH, et al.: Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005;22:111-122.
24. Antonsson L, Boketoft A, Garzino-Demo A, Olde B, and Owman C: Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4. AIDS 2003;17:2571-2579.
25. Karlsson I, Antonsson L, Shi Y, et al.: HIV biological variability unveiled: Frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 2003;17:2561-2569.
26. Merino R, Grillot DA, Simonian PL, et al.: Modulation of anti-IgM-induced B cell apoptosis by Bcl-xL and CD40 in WEHI-231 cells. Dissociation from cell cycle arrest and dependence on the avidity of the antibody-IgM receptor interaction. J Immunol 1995;155:3830-3838.
27. Woof JM: Immunology. Tipping the scales toward more effective antibodies. Science 2005;310:1442-1443.
28. Siberil S, Dutertre CA, Fridman WH, and Teillaud JL: FcgammaR: The key to optimize therapeutic antibodies? Crit Rev Oncol Hematol 2007;62:26-33.
29. Baccam M and Bishop GA: Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells. Eur J Immunol 1999;29:3855-3866.
30. Borrebaeck CA and Carlsson R: Human therapeutic antibodies. Curr Opin Pharmacol 2001;1:404-408.
31. Carter PJ: Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-357.